viewAerie Pharmaceuticals

Aerie Pharmaceuticals shares rocket as investors eye-up drug trial

Its treatment for lowering fluid pressure inside the eyeball had yielded “promising results”.

Close up shot of a human eye ball
Roclatan is being trialled to reduce pressure within the eye

Aerie Pharmaceuticals Inc. (NASDAQ:AERI) shares dominated the risers board on the small-cap Russell 2000 index on Thursday after the company announced successful 90-day primary efficacy data from the first phase III registration study, Mercury 1, on Roclatan.

The drug discovery group reported that its treatment for lowering fluid pressure inside the eyeball had yielded “promising results”.

A late-stage clinical trial showed that its treatment, Roclatan, significantly lowered pressure inside the eyeball compared to rival treatments.

Roclatan is a fixed-dose combination of Aerie’s lead candidate, Rhopressa (netarsudil ophthalmic solution) 0.02% and Pfizer Inc.’s (NYSE:PFE) Xalatan (latanoprost), the most widely-prescribed prostaglandin analogue (PGA).

Roclatan is being evaluated for its ability to lower intraocular pressure in patients with glaucoma or ocular hypertension.

Aerie shares ended up 44.9% at $30.61. Intraday the stock hit $34.69 – its highest level since April 2015.

Quick facts: Aerie Pharmaceuticals

Price: 22.74 USD

Market: NASDAQ
Market Cap: $1.05 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: The City Pub Group grows

A cold wet December meant admittedly slower trading for The City Pub Group (LON:CPC) but that hasn't dampened their appetite for growth. Just a few years ago, CEO Clive Watson headed up 30 watering holes but now has almost 50, with plans for new UK sites in Bath, Cambridge and Exeter. Watson...

1 hour, 1 minute ago

2 min read